Clinical Trials in Boston

Showing 2481-2500 of 15,299 trials

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

NCT06724016

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation Part is planned to establish the MTD or RDs for the randomized Dose-Ranging Part. Based on the results of the Dose-Escalation Part, additional eligible subjects will be randomized 1:1 into each dose level. After a comprehensive review of available data from both Dose-Escalation Part and Dose-Ranging Part, the RDEs to be tested in the Dose-Expansion Part are determined. Dose-Expansion Part is designed to assess the potential efficacy of HM16390 as a single agent and in combination with pembrolizumab when administered at the RDEs to subjects in indication-specific expansion cohorts.

Advanced or Metastatic Solid Tumors

Hanmi Pharmaceutical Company Limited292 participantsStarted Dec 2024

Boston, Massachusetts, United States • Detroit, Michigan, United States • Seongnam-si, Gyeonggi-do, South Korea +4 more locations

Active Not RecruitingNA< 1 mile

Bridge-Enhanced ACL Repair-Safety Study (BEAR Trial)

NCT02292004

This study will assess the safety and early efficacy of a newly developed device, bridge-enhanced scaffold (MIACH™,) used to repair a torn anterior cruciate ligament (ACL.) Ten participants will undergo surgery with the new device (Experimental Group) and 10 will undergo a standard ACL reconstruction surgery (Control Group.)

Anterior Cruciate Ligament InjuryAnterior Cruciate Ligament Tear

Miach Orthopaedics20 participantsStarted Jan 2015

Boston, Massachusetts, United States

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Bridge-Enhanced ACL Repair-Safety Study (BEAR Trial)

Find Trials by Condition in Boston

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

NeuroPathways Intervention for Brain Tumor Patients

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)

Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

A Feasibility Study Evaluating the Performance of Focused Multipolar Stimulation and Sound Coding in Adults.